Jefferies cuts Boston Scientific stock price target on growth outlook

Boston Scientific beat Q1 sales and EPS estimates at $5.20B and $0.80, but reduced 2026 organic growth guidance to 6.5%-8% from 10%-11% and cut 2026 EPS guidance to $3.34-$3.41 from $3.43-$3.49. Jefferies lowered its price target to $100 from $110 while keeping a Buy rating, citing issues in urology, cardiac rhythm management, and slower Watchman growth. The company also authorized a $2B share repurchase program, but the revised outlook and target cuts point to near-term pressure on the stock.

Analysis

The key issue is not the quarter itself but the reset in the company’s medium-term compounding rate. A downgrade from “double-digit growth” to high-single-digit growth compresses the stock’s quality multiple more than the modest EPS revision suggests, because healthcare equipment names are typically priced on durable runway rather than near-term beats. That makes the market’s reaction rational if investors had been anchoring on 10%+ organic growth as a structural floor.

Second-order, the pressure likely broadens beyond BSX. Slower Watchman and rhythm momentum imply fewer share gains in adjacent high-margin franchises, which can force heavier promo intensity or rep activity across competing structural heart and EP players. The bigger risk is that this is not a one-off product hiccup but an indication that the post-pandemic elective/procedural recovery is normalizing faster than consensus, which would also temper expectations for supplier order growth and implant mix.

The buyback announcement is supportive but mostly defensive unless the operating trend stabilizes. A $2B repurchase can cushion downside over the next 1-2 quarters, but it does not change the market’s focus on whether 2026 guidance was cut once or is the first step in a series of resets. If management can re-accelerate urology and show stabilization in rhythm/Watchman over the next two reporting cycles, the name can re-rate; if not, the stock can remain cheap for a reason.

Contrarian view: the selloff may be overdone if investors are extrapolating the guidance cut into a long-lived erosion story. At roughly this valuation, the stock is pricing in a much deeper structural problem than a sub-10% growth profile, and medtech franchises with strong cash flow often bottom before guidance does. The best asymmetry is not chasing the dip outright, but waiting for evidence that the revised base is real and then buying the first quarter where guide-down risk disappears.

Key Decisions for Investors

• Avoid adding to BSX immediately; wait 4-8 weeks for management commentary and channel checks on urology and Watchman before re-underwriting the 2026 base case. Risk/reward is poor until the market stops pricing in additional guidance resets.
• For existing longs, monetize part of the position via covered calls into the next earnings window; implied vol should stay elevated while investors debate whether the reset is one-time or multi-quarter. Use a 1-2 quarter horizon.
• Pair trade: long larger-cap medtech with steadier procedure mix vs short BSX if you want to express relative guidance-risk, especially over the next 1-3 months. The goal is to isolate execution variance from sector beta.
• If BSX stabilizes above the post-gap support and management confirms no further cuts, consider a tactical long with a 6-12 month horizon; the upside case is multiple expansion on low-double-digit FCF growth normalization, but only after the market de-risks guide revisions.
• Do not treat the buyback as a standalone bullish signal; if you want capital returns exposure, prefer names where repurchases are paired with stable or rising operating guidance.